- Home
- BL vs ZLAB Comparison
BL vs ZLAB Comparison
Compare BL & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BL | ZLAB |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2016 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BL | ZLAB |
|---|---|---|
| Price | $36.29 | $20.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 5 |
| Target Price | ★ $57.23 | $49.60 |
| AVG Volume (30 Days) | ★ 1.0M | 696.8K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 0.39 | N/A |
| Revenue | $177,031,000.00 | ★ $460,156,000.00 |
| Revenue This Year | $12.62 | $14.46 |
| Revenue Next Year | $10.90 | $29.47 |
| P/E Ratio | $93.10 | ★ N/A |
| Revenue Growth | ★ 43.78 | 15.33 |
| 52 Week Low | $31.75 | $15.96 |
| 52 Week High | $59.57 | $44.34 |
Technical Indicators
Market Signals| Indicator | BL | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 62.72 |
| Support Level | $35.37 | $17.11 |
| Resistance Level | $39.29 | $27.23 |
| Average True Range (ATR) | 1.81 | 0.67 |
| MACD | 0.13 | 0.21 |
| Stochastic Oscillator | 26.95 | 89.28 |
Price Performance
Historical ComparisonAbout BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.